AECOPD患者外周血EOS、D-D和NLR与肺通气功能的关系

doi:10.11958/20240704

天津医药 ›› 2024, Vol. 52 ›› Issue (12): 1261-1265.doi: 10.11958/20240704

AECOPD患者外周血EOS、D-D和NLR与肺通气功能的关系

刘燕¹(), 许靖¹, 马蕾¹, 曹冠亚², 赵凤德¹^,^△()

1 阜阳市第二人民医院呼吸科（邮编236000）
2 胸外科

收稿日期:2024-07-01 修回日期:2024-08-20 出版日期:2024-12-15 发布日期:2024-12-17
通讯作者: △E-mail：fyeyygt@126.com
作者简介:刘燕（1990），女，主治医师，主要从事慢性阻塞性肺疾病、哮喘、支气管扩张症、肺癌等方面研究。E-mail：fyeyly@163.com
基金资助:
阜阳市卫生健康委科研项目(FY2021-053);阜阳市“新型冠状病毒肺炎”科研项目(FY2020xg01)

The relationship between EOS, D-D and NLR in peripheral blood and pulmonary ventilation in patients with AECOPD

LIU Yan¹(), XU Jing¹, MA Lei¹, CAO Guanya², ZHAO Fengde¹^,^△()

1 Department of Respiratory
2 Department of Thoracic Surgery, Fuyang Second People's Hospital, Fuyang 236000, China

Received:2024-07-01 Revised:2024-08-20 Published:2024-12-15 Online:2024-12-17
Contact: △E-mail：fyeyygt@126.com

刘燕, 许靖, 马蕾, 曹冠亚, 赵凤德. AECOPD患者外周血EOS、D-D和NLR与肺通气功能的关系[J]. 天津医药, 2024, 52(12): 1261-1265.

LIU Yan, XU Jing, MA Lei, CAO Guanya, ZHAO Fengde. The relationship between EOS, D-D and NLR in peripheral blood and pulmonary ventilation in patients with AECOPD[J]. Tianjin Medical Journal, 2024, 52(12): 1261-1265.

摘要/Abstract

摘要：

目的探讨慢性阻塞性肺疾病急性加重期（AECOPD）患者外周血嗜酸性粒细胞（EOS）、D-二聚体（D-D）和中性粒细胞/淋巴细胞比值（NLR）变化及与肺通气功能的关系。方法分别选择AECOPD患者（观察组）和慢性阻塞性肺疾病（COPD）患者（对照组）各65例。收集患者基本资料并进行实验室指标检查，测定EOS、D-D水平，并计算NLR。检测肺功能指标第1秒用力呼气容积（FEV1）、第1秒用力呼气容积占用力肺活量百分比（FEV1/FVC）及血气指标动脉血氧分压[p（O₂）]和动脉血二氧化碳分压[p（CO₂）]。多因素Logistic回归分析AECOPD的影响因素。采用R4.2.3建立AECOPD的列线图模型并进行验证。结果与对照组比较，观察组EOS、D-D、NLR水平升高，FEV1、FEV1/FVC水平降低（P<0.05）。多因素Logistic回归分析结果显示，EOS、D-D、NLR升高以及FEV1/FVC、FEV1降低是患者发生AECOPD的独立危险因素（P<0.05）。AECOPD列线图模型的受试者工作特征（ROC）曲线下面积为0.817（95%CI：0.784~0.904），Hosmer-Lemeshow检验结果显示该模型的拟合优度较好（χ²=4.320，P>0.05）。EOS、D-D、NLR均与FEV1、FEV1/FVC呈正相关（P<0.05）。结论 EOS、D-D、NLR水平升高是影响AECOPD患者肺通气功能的危险因素，可作为评估肺通气功能的重要指标。

关键词: 肺疾病, 慢性阻塞性, 肺通气, 嗜酸粒细胞增多, D-二聚体, 中性粒细胞/淋巴细胞比值, 慢性阻塞性肺疾病急性加重期

Abstract:

Objective To investigate changes of peripheral blood eosinophils (EOS), D-dimer (D-D) and neutrophil/lymphocyte ratio (NLR) in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and their relationship with pulmonary ventilation function. Methods Sixty-five AECOPD patients (the observation group) and 65 COPD patients (the control group) were selected respectively and included in this study. Basic data were collected in the two groups of patients, and laboratory indexes were examined. EOS and D-D levels were determined, and NLR was calculated. The lung function indexes including the first second expiratory volume with exertion (FEV1), the first second expiratory volume with exertion as a percentage of expiratory lung capacity with exertion (FEV1/FVC), and blood gas indexes of arterial blood partial pressure of oxygen [p(O₂)] and arterial blood partial pressure of carbon dioxide [p(CO₂)] were detected. Multifactorial Logistic regression was used to analyze the influencing factors of AECOPD. The nomogram model of AECOPD was established and verified by R4.2.3. Results Compared with the control group, levels of EOS, D-D and NLR were elevated, and FEV1 and FEV1/FVC levels were reduced in the observation group (P<0.05). Multifactorial Logistic regression analysis showed that elevated EOS, D-D and NLR, and reduced FEV1/FVC and FEV1 were independent risk factors for patients with AECOPD (P<0.05). The area under the receiver operating characteristic (ROC) curve of AECOPD nomogram model was 0.817 (95%CI: 0.784-0.904 ), and the Hosmer-Lemeshow test showed goodness of fit of the model (χ²=4.320, P>0.05). EOS, D-D and NLR were positively correlated with FEV1 and FEV1/FVC (P<0.05). Conclusion The elevated levels of EOS, D-D and NLR are risk factors that affect pulmonary ventilation in AECOPD patients, which can be used as an important indicator to evaluate pulmonary ventilation function.

Key words: pulmonary disease, chronic obstructive, pulmonary ventilation, eosinophilia, D-dimer, neutrophil/lymphocyte ratio, acute exacerbation of chronic obstructive pulmonary disease

中图分类号:

R563

图/表 6

参考文献 20

[1]	BRASSINGTON K, SELEMIDIS S, BOZINOVSKI S, et al. Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics[J]. Clin Sci (Lond), 2022, 136(6):405-423. doi: 10.1042/CS20210835.
[2]	DIAZ A A, OREJAS J L, GRUMLEY S, et al. Airway-occluding mucus plugs and mortality in patients with chronic obstructive pulmonary disease[J]. JAMA, 2023, 329(21):1832-1839. doi: 10.1001/jama.2023.2065.
[3]	苏振磊, 杨万春, 韩天龙. 血清CXCL9和SFRP1在AECOPD合并肺栓塞患者中的表达及对预后的影响[J]. 天津医药, 2023, 51(4):427-431.
	SU Z L, YANG W C, HAN T L. Expression of serum CXCL9 and SFRP1 in patients with AECOPD combined with pulmonary embolism and its effect on prognosis[J]. Tianjin Med J, 2023, 51(4):427-431. doi:10.11958/20221267.
[4]	WU C. Research progress of serum eosinophil in chronic obstructive pulmonary disease and asthma[J]. Open Life Sci, 2023, 18(1):20220779. doi:10.1515/biol-2022-0779.
[5]	ZHANG C, SONG J, WANG J. Meta-analysis of peripheral blood eosinophils in clinical testing of chronic obstructive pulmonary disease patients[J]. Postepy Dermatol Alergol, 2024, 41(2):155-163. doi:10.5114/ada.2024.139124.
[6]	李娜, 朱宏霞, 朱丹, 等. 血清鸢尾素和热休克蛋白27及D-二聚体水平对慢性阻塞性肺疾病急性加重期合并肺栓塞的鉴别价值及其与预后的关系探讨[J]. 临床急诊杂志, 2022, 23(5):337-342,347.
	LI N, ZHU H X, ZHU D, et al. Discussion on the differential value of serum irisin and heat shock protein 27 and D-dimer levels for pulmonary embolism combined with acute exacerbation of chronic obstructive pulmonary disease and its relationship with prognosis[J]. J Clin Emerg, 2022, 23(5):337-342,347. doi:10.13201/j.issn.1009-5918.2022.05.008.
[7]	刘玉花, 马奎军, 樊晓雁, 等. PLR、NLR、CRP与老年AECOPD患者病情严重程度、近期预后的关系[J]. 现代生物医学进展, 2023, 23(15):2947-2950,2995.
	LIU Y H, MA K J, FAN X Y, et al. Relationship between PLR,NLR,CRP and disease severity and recent prognosis of elderly AECOPD patients[J]. Progress in Modern Biomedicine, 2023, 23(15):2947-2950,2995. doi:10.13241/j.cnki.pmb.2023.15.028.
[8]	王凤燕, 张冬莹, 梁振宇, 等. 面向全科医生的《慢性阻塞性肺疾病诊治指南(2021年修订版)》解读[J]. 中国全科医学, 2021, 24(29):3660-3663,3677.
	WANG F Y, ZHANG D Y, LIANG Z Y, et al. Interpretation of the guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease (2021 revision) for general practitioners[J]. Chin Gen Prac, 2021, 24(29):3660-3663,3677. doi:10.12114/j.issn.1007-9572.2021.01.304.
[9]	RAMYA P A, MOHAPATRA M M, SAKA V K, et al. Haematological and inflammatory biomarkers among stable COPD and acute exacerbations of COPD patients[J]. Sultan Qaboos Univ Med J, 2023, 23(2):239-244. doi:10.18295/squmj.12.2022.062.
[10]	YE M, ZHANG R. Effect of humidified high-flow nasal cannula oxygen therapy with a pulmonary infection control window as a ventilation switching indication in combination with atomizing inhalation of terbutaline on the lung function of patients with acute exacerbation of COPD[J]. Acta Med Okayama, 2024, 78(3):271-279. doi: 10.18926/AMO/67202.
[11]	康睿, 刘慧霞. 肺部感染控制窗序贯通气在慢性阻塞性肺疾病急性加重期合并呼吸衰竭治疗中的应用价值研究[J]. 陕西医学杂志, 2022, 51(3):342-346.
	KANG R, LIU H X. Study on the application value of sequential ventilation with lung infection control window in the treatment of combined respiratory failure during acute exacerbation of chronic obstructive pulmonary disease[J]. Shaanxi Medical Journal, 2022, 51(3):342-346. doi:10.3969/j.issn.1000-7377.2022.03.018.
[12]	YANG I A, JENKINS C R, SALVI S S. Chronic obstructive pulmonary disease in never-smokers:risk factors,pathogenesis,and implications for prevention and treatment[J]. Lancet Respir Med, 2022, 10(5):497-511. doi:10.1016/S2213-2600(21)00506-3.
[13]	WEI T, WANG X, LANG K, et al. Low eosinophil phenotype predicts noninvasive mechanical ventilation use in patients with hospitalized exacerbations of COPD[J]. J Inflamm Res, 2022, 15:1259-1271. doi:10.2147/JIR.S343918.
[14]	陈娟, 关微, 徐蕊华. 百令胶囊联合鲮甲司坦治疗AECOPD的疗效及对EOS、PCT、肺功能及应激反应指标的影响[J]. 中国医药导刊, 2023, 25(10):1045-1050.
	CHEN J, GUAN W, XU R H. The efficacy of Bailing capsule combined with pangolinan in the treatment of AECOPD and its effect on EOS,PCT,lung function and stress response indexes[J]. Chin J Med Guide, 2023, 25(10):1045-1050. doi:10.3969/j.issn.1009-0959.2023.10.016.
[15]	RYDELL N, NAGAO M, MOVÉRARE R, et al. Serum eosinophilic cationic protein is a reliable biomarker for childhood asthma[J]. Int Arch Allergy Immunol, 2022, 183(7):744-752. doi: 10.1159/000521890.
[16]	SUNG E A, PARK M H, HENEGARIU O, et al. Dickkopf1 promotes pulmonary fibrosis upon bleomycin-induced lung injury[J]. Am J Pathol, 2023, 193(9):1130-1142. doi: 10.1016/j.ajpath.2023.05.009.
[17]	赖育庭, 申严, 叶春幸, 等. 不同程度AECOPD患者血清25-(OH)Vit D和IGF-1及SF水平及其与肺功能相关性[J]. 热带医学杂志, 2023, 23(7):1007-1010.
	LAI Y T, SHEN Y, YE C X, et al. Serum 25-(OH)Vit D and IGF-1 and SF levels and their correlation with lung function in patients with different degrees of AECOPD[J]. Journal of Tropical Medicine, 2023, 23(7):1007-1010. doi:10.3969/j.issn.1672-3619.2023.07.026.
[18]	左艳华, 刘靓, 许化恒, 等. NLR、MLR、PLR在结缔组织病相关性间质性肺炎诊治中变化情况及临床意义[J]. 临床军医杂志, 2022, 50(3):286-288.
	ZUO Y H, LIU L, XU H H, et al. Changes and clinical significance of NLR,MLR and PLR in the diagnosis and treatment of connective tissue disease-associated interstitial pneumonia[J]. Clinical Journal of Medical Officers, 2022, 50(3):286-288. doi:10.16680/j.1671-3826.2022.03.17.
[19]	HU T, LIU X, LIU Y. Usefulness of glucose to lymphocyte ratio to predict in-hospital mortality in patients with AECOPD admitted to the intensive care unit[J]. COPD, 2022, 19(1):158-165. doi: 10.1080/15412555.2022.2052272.
[20]	李术环, 徐慧莲, 郝秋红. PCT、D-D、NLR、Cys-C与慢性阻塞性肺疾病急性加重期患者的相关性及对预后的预测价值[J]. 中华保健医学杂志, 2023, 25(4):426-428.
	LI S H, XU H L, HAO Q H. Correlation of PCT,D-D,NLR and Cys-C with patients with acute exacerbation of chronic obstructive pulmonary disease and its predictive value for prognosis[J]. Chin J Heal Care Med, 2023, 25(4):426-428. doi:103969/j.issn.1674-3245.2023.04.016.

组别	n		性别（男/女）	年龄/岁		BMI/（kg/m²）		高血压		糖尿病	吸烟		心率/（次/min）		尿酸/（μmoL/L）		TC/（mmoL/L）		HDL-C/（mmoL/L）
对照组	65		41/24	59.31±8.51		24.17±1.16		41（63.07）		39（60.00）	52（80.00）		77.65±19.83		365.49±49.42		4.59±1.08		1.34±0.30
观察组	65		42/23	57.49±8.80		24.04±1.23		39（60.00）		36（55.38）	54（83.07）		79.15±20.18		379.48±46.12		4.25±1.27		1.28±0.32
χ²或t			0.033	1.199		0.620		0.130		0.284	0.204		0.427		1.669		1.644		0.929
组别		LDL-C/（mmoL/L）			TG/（mmoL/L）		EOS/（×10⁹/L）		D-D/（mg/L）			NLR		FEV1/FVC/%		p（CO₂）/mmHg		p（O₂）/mmHg		FEV1/%
对照组		2.62±1.98			1.56±0.68		0.39±0.06		244.28±25.41			7.96±1.08		51.25±4.89		45.08±13.24		73.68±15.34		55.04±8.64
观察组		2.76±1.07			1.59±0.86		0.45±0.08		265.40±28.45			9.59±2.52		47.29±4.26		46.57±14.08		69.59±15.07		48.84±7.74
t		0.480			0.293		4.898^＊		4.462^＊			4.793^＊		4.918^＊		0.626		1.537		4.316^＊

组别	n		性别（男/女）	年龄/岁		BMI/（kg/m²）		高血压		糖尿病	吸烟		心率/（次/min）		尿酸/（μmoL/L）		TC/（mmoL/L）		HDL-C/（mmoL/L）
对照组	65		41/24	59.31±8.51		24.17±1.16		41（63.07）		39（60.00）	52（80.00）		77.65±19.83		365.49±49.42		4.59±1.08		1.34±0.30
观察组	65		42/23	57.49±8.80		24.04±1.23		39（60.00）		36（55.38）	54（83.07）		79.15±20.18		379.48±46.12		4.25±1.27		1.28±0.32
χ²或t			0.033	1.199		0.620		0.130		0.284	0.204		0.427		1.669		1.644		0.929
组别		LDL-C/（mmoL/L）			TG/（mmoL/L）		EOS/（×10⁹/L）		D-D/（mg/L）			NLR		FEV1/FVC/%		p（CO₂）/mmHg		p（O₂）/mmHg		FEV1/%
对照组		2.62±1.98			1.56±0.68		0.39±0.06		244.28±25.41			7.96±1.08		51.25±4.89		45.08±13.24		73.68±15.34		55.04±8.64
观察组		2.76±1.07			1.59±0.86		0.45±0.08		265.40±28.45			9.59±2.52		47.29±4.26		46.57±14.08		69.59±15.07		48.84±7.74
t		0.480			0.293		4.898^＊		4.462^＊			4.793^＊		4.918^＊		0.626		1.537		4.316^＊

变量	β	SE	Wald χ²	P	OR（95%CI）
EOS	11.139	3.742	8.862	0.003	68 831.167（11.935~ 1 054 350.339）
D-D	0.025	0.010	6.506	0.011	1.025（1.006~1.045）
NLR	0.393	0.138	8.109	0.004	1.481（1.130~1.941）
FEV1/FVC	-0.176	0.054	10.527	0.001	0.839（0.755~0.933）
FEV1	-0.112	0.032	12.138	<0.001	0.894（0.839~0.952）
常数项	0.160	4.235	0.001	0.970	1.173

变量	β	SE	Wald χ²	P	OR（95%CI）
EOS	11.139	3.742	8.862	0.003	68 831.167（11.935~ 1 054 350.339）
D-D	0.025	0.010	6.506	0.011	1.025（1.006~1.045）
NLR	0.393	0.138	8.109	0.004	1.481（1.130~1.941）
FEV1/FVC	-0.176	0.054	10.527	0.001	0.839（0.755~0.933）
FEV1	-0.112	0.032	12.138	<0.001	0.894（0.839~0.952）
常数项	0.160	4.235	0.001	0.970	1.173

AECOPD患者外周血EOS、D-D和NLR与肺通气功能的关系

The relationship between EOS, D-D and NLR in peripheral blood and pulmonary ventilation in patients with AECOPD

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 6

参考文献 20

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张兰英, 张福安, 刘茂茂, 陈杰, 周健, 刘钰婷, 欧阳瑶. CD1a⁺和CD83⁺树突状细胞在COPD小鼠肺组织中的分布及意义[J]. 天津医药, 2024, 52(9): 913-916.
[2]	李冬生, 秦艺榕, 乔曼, 迟航, 崔青敏, 李晓秋. 清咳平喘颗粒对COPD急性加重期的临床疗效[J]. 天津医药, 2024, 52(8): 854-857.
[3]	李梦涛, 王迁. 结缔组织病相关间质性肺病：从发病机制研究到“双达标”治疗策略[J]. 天津医药, 2024, 52(7): 673-678.
[4]	张国华, 张令令, 高兰, 罗俊丽, 申雅文, 刘磊, 王玉华. 结缔组织病相关间质性肺病合并肺癌16例临床分析[J]. 天津医药, 2024, 52(7): 687-690.
[5]	尹韦玉, 廖红丽, 刘媛. SS相关抗体在特发性炎症性肌病及其相关间质性肺炎中的临床意义[J]. 天津医药, 2024, 52(7): 695-700.
[6]	刘智超, 李霄鹤, 周红刚, 张娜. 特发性炎性肌病相关间质性肺疾病动物模型概述[J]. 天津医药, 2024, 52(7): 709-713.
[7]	赵术彤, 丁运, 李月川, 赵晓赟, 耿华, 徐美林. 轻度慢性阻塞性肺疾病的病理特征及其与炎性因子的相关性[J]. 天津医药, 2024, 52(6): 643-647.
[8]	叶朝阳, 马建中, 李后俊, 魏鲲鹏. 急性胰腺炎患者外周血TLR4、IL-1β、NLR水平与疾病进展和预后的关系[J]. 天津医药, 2024, 52(6): 648-652.
[9]	冯李婷, 李莉, 谢鑫, 王星. 天津地区部分居民慢性阻塞性肺疾病影响因素分析[J]. 天津医药, 2024, 52(4): 427-431.
[10]	袁昌芬, 许颖, 郭韫凡, 吴云涛, 王秀艳, 张景义. 中性粒细胞/淋巴细胞比值与白塞病疾病活动性的相关性[J]. 天津医药, 2024, 52(3): 311-314.
[11]	屠昌明, 田园, 汪鹏程, 任鹏, 赵寅生. SII、RAR与AECOPD患者病情严重程度及并发呼吸衰竭的关系[J]. 天津医药, 2024, 52(12): 1317-1321.
[12]	于志鸿, 王小琴. 欧前胡素衍生物对COPD肺泡Ⅱ型细胞活性及耐药蛋白的影响[J]. 天津医药, 2024, 52(11): 1127-1130.
[13]	冯靖, 刘丹, 万南生, 王杰, 句仁华, 谢巍, 田羽. 导向注药套管经鼻悬吊留置伴或不伴锚定治疗肺部霉菌病的操作流程[J]. 天津医药, 2024, 52(1): 83-86.
[14]	苏振磊, 杨万春, 韩天龙. 血清CXCL9和SFRP1在AECOPD合并肺栓塞患者中的表达及对预后的影响[J]. 天津医药, 2023, 51(4): 427-431.
[15]	张凤, 方著, 袁艺, 周芸慧, 张国晋, 蒲红, 刘欢. 慢性阻塞性肺疾病患者HRCT定量指标与肺功能的相关性研究[J]. 天津医药, 2023, 51(3): 320-324.